The Italian Transthyretin Amyloidosis Web-Network

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-13

Study Completion Date

2027-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims, by generating a large registry of patients with ATTR amyloidosis, including data at diagnosis and during follow up, to describe the natural history of ATTR amyloidosis in a real-world setting and to define and validate prognostic models, response criteria applicable at any point of the disease. The registry will also be used for data sharing and to allow the possibility of a close collaboration amongst the amyloidosis experts of the ARTC and all the physicians around the Country involved in the diagnosis and management of systemic amyloidosis. Thanks to the online registry, the diagnostic facility of the ARTC will be made available to requesting physicians.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comprehensive Program for Hereditary Transthyretin Amyloidosis

NCT07213297

Amyloidosis in Transthyretin (TTR) Amyloidosis, Familial

NOT_YET_RECRUITING

Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis

NCT03431896

Amyloidosis Amyloid Amyloid Neuropathies, Familial +4 more

ACTIVE_NOT_RECRUITING

Neuropathy in Patients Monitored for Wild-type TTR Cardiac Amyloidosis (Non-mutated)

NCT04828928

Wild-type Amyloid Cardiopathy

COMPLETED NA

A Registry of AL Amyloidosis (ReAL)

NCT04839003

AL Amyloidosis

RECRUITING

Promoting Diagnosis and Management of AL in Italy (ProDigALIty)

NCT06383143

AL Amyloidosis Smoldering Multiple Myeloma Monoclonal Gammopathy of Undetermined Significance

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ATTR Amyloidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Suspected diagnosis of systemic and localized amyloidosis;
2. age .18 years;
3. ability to understand and willingness to sign an informed consent (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted);
4. planned (or ongoing) follow-up at participating center.